First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic

BACKGROUND: The FLAURA trial demonstrated improved overall survival (OS) with first-line osimertinib for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). We studied the efficacy and safety of osimertinib in a cohort treated during the coronav...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakkunarajah, Suganija, Truong, Pauline T., Bone, Jeffrey N., Hughesman, Curtis, Yip, Stephen, Alex, Deepu, Hart, Jason, Pollock, Philip, Egli, Sarah, Clarkson, Melissa, Lesperance, Mary, Ksienski, Doran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413024/
https://www.ncbi.nlm.nih.gov/pubmed/37577326
http://dx.doi.org/10.21037/tlcr-23-81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413024/
https://www.ncbi.nlm.nih.gov/pubmed/37577326
http://dx.doi.org/10.21037/tlcr-23-81

Ejemplares similares